Last reviewed · How we verify
HEPATITIS B SURFACE ANTIGEN
Hepatitis B surface antigen (HBsAg) is a viral protein used as an immunogen to stimulate the body's immune system to produce protective antibodies against hepatitis B virus infection.
Hepatitis B surface antigen (HBsAg) is a viral protein used as an immunogen to stimulate the body's immune system to produce protective antibodies against hepatitis B virus infection. Used for Prevention of hepatitis B virus infection, Immunization of infants, children, and adults against hepatitis B.
At a glance
| Generic name | HEPATITIS B SURFACE ANTIGEN |
|---|---|
| Sponsor | Central Hospital, Nancy, France |
| Drug class | vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
HBsAg is a component of the hepatitis B virus envelope that is produced recombinantly or derived from infected plasma. When administered as a vaccine, it triggers both humoral and cellular immune responses, leading to the production of anti-HBs antibodies that provide immunity against hepatitis B infection. This antigen has been a cornerstone of hepatitis B vaccination strategies for decades.
Approved indications
- Prevention of hepatitis B virus infection
- Immunization of infants, children, and adults against hepatitis B
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Headache
- Myalgia
Key clinical trials
- Evaluation of Patients With Liver Disease
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
- Fungal Infection Susceptibility
- Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
- Evaluation of Patient Care Support for Cirrhosis and/or Liver Transplants
- Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV (PHASE2)
- The Mechanistic Biology of Primary Immunodeficiency Disorders
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HEPATITIS B SURFACE ANTIGEN CI brief — competitive landscape report
- HEPATITIS B SURFACE ANTIGEN updates RSS · CI watch RSS
- Central Hospital, Nancy, France portfolio CI